Xtandi is a brand-name prescription drug used to treat certain types of prostate cancer [1]. It is a type of oral medication that works by blocking the activity of androgen receptors, which are proteins that fuel the growth of prostate cancer cells [2]. The active ingredient in Xtandi is enzalutamide [1].
What types of prostate cancer does Xtandi treat?
Xtandi is approved to treat prostate cancer that is no longer responding to treatments designed to lower testosterone (castration-resistant prostate cancer) [3]. This includes prostate cancer that has spread to other parts of the body (metastatic castration-resistant prostate cancer) and prostate cancer that has not spread but is likely to spread (non-metastatic castration-resistant prostate cancer) [3].
How does Xtandi work?
Xtandi is an androgen receptor inhibitor [1]. It works by preventing androgens, such as testosterone, from binding to androgen receptors in prostate cancer cells [1]. This action helps to slow or stop the growth of prostate cancer cells [1].
What are the potential side effects of Xtandi?
Common side effects associated with Xtandi can include fatigue, back pain, diarrhea, joint pain, hot flashes, and headache [2]. More serious side effects, though less common, can occur and may include seizures, posterior reversible encephalopathy syndrome (PRES), and cardiovascular events [2]. Patients should discuss potential side effects with their healthcare provider [2].
When does Xtandi's patent protection expire?
The patent landscape for Xtandi is complex, with multiple patents covering the drug [4]. Information on specific patent expiry dates for Xtandi can be found on DrugPatentWatch.com [4].
Who manufactures Xtandi?
Xtandi is developed and marketed by Astellas Pharma and Pfizer [1][5].
What are the alternatives to Xtandi for prostate cancer treatment?
Treatment options for prostate cancer vary depending on the stage and type of cancer. Alternatives may include other hormone therapies, chemotherapy, radiation therapy, surgery, and immunotherapy [6]. The best treatment approach is determined by a patient's specific medical condition and in consultation with their oncologist [6].